Apnimed (APMD) investor relations material

Executive summary

• Completed Phase 3 trials for Oxnimbi (AD109), submitted NDA to FDA in April 2026, with PDUFA date set for February 28, 2027; trials met primary and key secondary endpoints, showing significant efficacy and favorable safety profile.

• Divested 50% interest in SASS joint venture to Shionogi in April 2026 for $100M upfront and potential $50M milestone, focusing resources on Oxnimbi commercialization.

• Completed IPO in August 2026, raising $220.8M gross ($200.4M net) and began trading on Nasdaq Global Select Market, strengthening liquidity for commercialization plans.

• Monetized interest in Shionogi-Apnimed Sleep Science, generating $100M upfront, with potential for additional milestone and royalty payments.

• Strengthened leadership team with key executive appointments.

Financial highlights

• Net income of $193.7M for the six months ended June 30, 2026, compared to a net loss of $98.1M in the prior year, driven by SASS divestiture and reversal of deposit liability.

• Net income for Q2 2026 was $125.9M, compared to a net loss of $69.5M in Q2 2025.

• Revenue from related party (SASS) was $96.9M for the six months ended June 30, 2026, up from $20.2M in the prior year, primarily due to a change in estimated costs and contract modifications.

• Operating expenses decreased 24% year-over-year to $40.6M, with R&D expenses down 54% to $18.0M as Phase 3 trials concluded; G&A expenses increased over 100% to $12.7M due to commercial readiness.

• Cash and cash equivalents were $172.8M as of June 30, 2026, prior to IPO proceeds.

Outlook and guidance

• Cash on hand plus IPO proceeds expected to fund operations through mid-2028; earliest commercial revenue from Oxnimbi anticipated in 2027, pending FDA approval.

• Advancing commercial readiness activities for a potential U.S. launch of Oxnimbi, pending FDA approval.

• Expenses expected to increase with commercialization activities, including sales, marketing, and manufacturing scale-up.

• Additional funding may be required for pipeline expansion or if regulatory/commercialization timelines are delayed.

• Anticipates significant commercial opportunity given the large untreated OSA population in the U.S.